Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JS 015

Next Previous
Drug Profile

JS 015

Alternative Names: JS-015

Latest Information Update: 22 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shanghai Junshi Biosciences
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; DKK1 protein inhibitors; Myeloid-derived suppressor cell inhibitors; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 17 Apr 2024 Fudan University plans a phase I/II FD-IMPACT trial for Pancreatic Cancer in China (IV) (NCT06370754)
  • 22 Nov 2023 Shanghai Junshi Bioscience plans a phase I/II trial for Solid Tumor (Late-stage disease, Combination therapy, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) (IV) in November 2023 (NCT06139211)
  • 20 Mar 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (IV) (NCT05770310)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top